Published in JAMA on June 08, 2011
Screening for Prostate Cancer in Older Patients (PLCO Screening Trial) | NCT00002540
Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet (2015) 7.50
Risk Algorithm Using Serial Biomarker Measurements Doubles the Number of Screen-Detected Cancers Compared With a Single-Threshold Rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening. J Clin Oncol (2015) 5.37
Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer (2011) 5.28
Impact of endoscopic surveillance on mortality from Barrett's esophagus-associated esophageal adenocarcinomas. Gastroenterology (2013) 4.43
Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers. Sci Transl Med (2013) 2.58
The role of the fallopian tube in the origin of ovarian cancer. Am J Obstet Gynecol (2013) 2.47
Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium. J Natl Cancer Inst (2014) 2.40
Ovarian cancer and smoking: individual participant meta-analysis including 28,114 women with ovarian cancer from 51 epidemiological studies. Lancet Oncol (2012) 2.33
Trends in relative survival for ovarian cancer from 1975 to 2011. Obstet Gynecol (2015) 2.22
Ovarian cancer and body size: individual participant meta-analysis including 25,157 women with ovarian cancer from 47 epidemiological studies. PLoS Med (2012) 2.22
Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199. J Clin Oncol (2014) 2.19
Screening and cervical cancer cure: population based cohort study. BMJ (2012) 1.99
Results of annual screening in phase I of the United Kingdom familial ovarian cancer screening study highlight the need for strict adherence to screening schedule. J Clin Oncol (2012) 1.90
Quantification of harms in cancer screening trials: literature review. BMJ (2013) 1.77
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer (2015) 1.53
Routine bimanual pelvic examinations: practices and beliefs of US obstetrician-gynecologists. Am J Obstet Gynecol (2012) 1.52
Longitudinal screening algorithm that incorporates change over time in CA125 levels identifies ovarian cancer earlier than a single-threshold rule. J Clin Oncol (2012) 1.48
Risk-reducing salpingo-oophorectomy and ovarian cancer screening in 1077 women after BRCA testing. JAMA Intern Med (2013) 1.43
Potential role of HE4 in multimodal screening for epithelial ovarian cancer. J Natl Cancer Inst (2011) 1.39
Ovarian Cancer Is an Imported Disease: Fact or Fiction? Curr Obstet Gynecol Rep (2012) 1.23
The role of microRNAs in ovarian cancer. Biomed Res Int (2014) 1.15
S3-Guideline on Diagnostics, Therapy and Follow-up of Malignant Ovarian Tumours: Short version 1.0 - AWMF registration number: 032/035OL, June 2013. Geburtshilfe Frauenheilkd (2013) 1.15
MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress. Mol Cancer (2014) 1.10
Ovarian cancer screening--current status, future directions. Gynecol Oncol (2013) 1.06
Protein biomarkers of ovarian cancer: the forest and the trees. Future Oncol (2012) 1.05
In 2014, can we do better than CA125 in the early detection of ovarian cancer? World J Biol Chem (2014) 1.04
Methylation of cell-free circulating DNA in the diagnosis of cancer. Front Mol Biosci (2015) 1.04
Combined and interactive effects of environmental and GWAS-identified risk factors in ovarian cancer. Cancer Epidemiol Biomarkers Prev (2013) 1.02
Population distribution of lifetime risk of ovarian cancer in the United States. Cancer Epidemiol Biomarkers Prev (2015) 0.99
The prostate, lung, colorectal, and ovarian cancer screening trial and its associated research resource. J Natl Cancer Inst (2013) 0.98
Major clinical research advances in gynecologic cancer in 2011. J Gynecol Oncol (2012) 0.97
Recommendations on routine screening pelvic examination: Canadian Task Force on Preventive Health Care adoption of the American College of Physicians guideline. Can Fam Physician (2016) 0.97
Biomarker testing for ovarian cancer: clinical utility of multiplex assays. Mol Diagn Ther (2013) 0.96
Ovarian Cancer Risk Factors by Histologic Subtype: An Analysis From the Ovarian Cancer Cohort Consortium. J Clin Oncol (2016) 0.96
Analysis of second-harmonic-generation microscopy in a mouse model of ovarian carcinoma. J Biomed Opt (2012) 0.94
Gender-specific differences in muscle-invasive bladder cancer: the concept of sex steroid sensitivity. World J Urol (2013) 0.94
Longitudinal evaluation of CA-125 velocity and prediction of ovarian cancer. Gynecol Oncol (2011) 0.93
Increasing awareness of gynaecological cancer symptoms: a GP perspective. Br J Gen Pract (2014) 0.93
Assessing the risk of ovarian malignancy in asymptomatic women with abnormal CA 125 and transvaginal ultrasound scans in the prostate, lung, colorectal, and ovarian screening trial. Obstet Gynecol (2013) 0.92
A Prospective Evaluation of Early Detection Biomarkers for Ovarian Cancer in the European EPIC Cohort. Clin Cancer Res (2016) 0.92
Precursors of ovarian cancer in the fallopian tube: serous tubal intraepithelial carcinoma--an update. J Obstet Gynaecol Res (2014) 0.92
Abnormal CA-125 levels in menopausal women without ovarian cancer. Gynecol Oncol (2014) 0.91
Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines From the European Group on Tumor Markers. Int J Gynecol Cancer (2016) 0.91
Personalized Circulating Tumor DNA Biomarkers Dynamically Predict Treatment Response and Survival In Gynecologic Cancers. PLoS One (2015) 0.90
Integrin inhibitors as a therapeutic agent for ovarian cancer. J Oncol (2011) 0.90
Ultrasound molecular imaging in a human CD276 expression-modulated murine ovarian cancer model. Clin Cancer Res (2014) 0.89
Symptom triggered screening for ovarian cancer: a pilot study of feasibility and acceptability. Gynecol Oncol (2011) 0.88
Screening for cancer with molecular markers: progress comes with potential problems. Nat Rev Cancer (2012) 0.88
Interpretation of single and serial measures of HE4 and CA125 in asymptomatic women at high risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev (2012) 0.87
Impact of screening test performance and cost on mortality reduction and cost-effectiveness of multimodal ovarian cancer screening. Cancer Prev Res (Phila) (2012) 0.86
Finding ovarian cancer. J Natl Cancer Inst (2012) 0.86
Tumour markers and kidney function: a systematic review. Biomed Res Int (2014) 0.85
Endometrial and ovarian cancer in lynch syndrome. Clin Colon Rectal Surg (2012) 0.84
Quantitative multiparametric MRI of ovarian cancer. J Magn Reson Imaging (2013) 0.84
Evaluating the risk of ovarian cancer before surgery using the ADNEX model: a multicentre external validation study. Br J Cancer (2016) 0.84
Oophorectomy: the debate between ovarian conservation and elective oophorectomy. Menopause (2013) 0.84
Early detection of ovarian and fallopian tube cancer by examination of cytological samples from the endometrial cavity. Br J Cancer (2013) 0.84
Ovarian cancer biomarker discovery based on genomic approaches. J Cancer Prev (2013) 0.84
Transvaginal ultrasonography in ovarian cancer screening: current perspectives. Int J Womens Health (2013) 0.84
Opportunistic salpingectomy for ovarian cancer prevention. Gynecol Oncol Res Pract (2015) 0.84
Proteomics of ovarian cancer: functional insights and clinical applications. Cancer Metastasis Rev (2015) 0.84
A multiplexable, microfluidic platform for the rapid quantitation of a biomarker panel for early ovarian cancer detection at the point-of-care. Cancer Prev Res (Phila) (2014) 0.83
Non-compliance with the initial screening exam visit in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Prev Med (2014) 0.83
A branching process model of ovarian cancer. J Theor Biol (2012) 0.83
Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study. PLoS Med (2016) 0.83
Genetic testing for hereditary cancer predisposition: BRCA1/2, Lynch syndrome, and beyond. Gynecol Oncol (2016) 0.83
Validation of a Biomarker Panel and Longitudinal Biomarker Performance for Early Detection of Ovarian Cancer. Int J Gynecol Cancer (2016) 0.83
Metformin and phenethyl isothiocyanate combined treatment in vitro is cytotoxic to ovarian cancer cultures. J Ovarian Res (2012) 0.83
Biomarkers and endosalpingiosis in the ovarian and tubal microenvironment of women at high-risk for pelvic serous carcinoma. Am J Cancer Res (2014) 0.83
Analysis of serial ovarian volume measurements and incidence of ovarian cancer: implications for pathogenesis. J Natl Cancer Inst (2014) 0.83
Risk of extracolonic cancers for people with biallelic and monoallelic mutations in MUTYH. Int J Cancer (2016) 0.83
Clinical relevance of circulating cell-free microRNAs in ovarian cancer. Mol Cancer (2016) 0.83
Validation of LRG1 as a potential biomarker for detection of epithelial ovarian cancer by a blinded study. PLoS One (2015) 0.82
Ovarian cancer: a molecularly insidious disease. Chin J Cancer (2015) 0.82
Update on first-line treatment of advanced ovarian carcinoma. Int J Womens Health (2013) 0.82
Identifying post-menopausal women at elevated risk for epithelial ovarian cancer. Gynecol Oncol (2015) 0.82
Value of symptom-triggered diagnostic evaluation for ovarian cancer. Obstet Gynecol (2014) 0.82
The effects of 17β-estradiol and a selective estrogen receptor modulator, bazedoxifene, on ovarian carcinogenesis. Gynecol Oncol (2011) 0.82
Fallopian Tube Ligation or Salpingectomy as Means for Reducing Risk of Ovarian Cancer. AMA J Ethics (2015) 0.82
New views on the pathogenesis of high-grade pelvic serous carcinoma with suggestions for advancing future research. Gynecol Oncol (2012) 0.82
Adequacy of family history taking in ovarian cancer patients: a population-based study. Fam Cancer (2012) 0.82
Participation of low-income women in genetic cancer risk assessment and BRCA 1/2 testing: the experience of a safety-net institution. J Community Genet (2015) 0.81
OVSCORE - a validated score to identify ovarian cancer patients not suitable for primary surgery. Oncol Lett (2014) 0.81
A patient with tuberculous peritonitis with very high serum CA 125. BMJ Case Rep (2012) 0.81
Ovarian cancer screening and mortality. JAMA (2011) 0.81
Issues of ovarian cancer survivors in the USA: a literature review. Support Care Cancer (2013) 0.81
Major clinical research advances in gynecologic cancer in 2015. J Gynecol Oncol (2016) 0.81
Views of general practitioners on the role of CA125 in primary care to diagnose ovarian cancer. BMC Womens Health (2013) 0.80
Relative Quantification and Higher-Order Modeling of the Plasma Glycan Cancer Burden Ratio in Ovarian Cancer Case-Control Samples. J Proteome Res (2015) 0.80
microRNA-126 suppresses PAK4 expression in ovarian cancer SKOV3 cells. Oncol Lett (2015) 0.80
Photoacoustic Imaging in Oncology: Translational Preclinical and Early Clinical Experience. Radiology (2016) 0.79
Comparison of HE4, CA125, and Risk of Ovarian Malignancy Algorithm in the Prediction of Ovarian Cancer in Korean Women. J Korean Med Sci (2015) 0.79
A randomised controlled trial comparing surgical intervention rates between two protocols for the management of asymptomatic adnexal tumours in postmenopausal women. BMJ Open (2012) 0.79
Extended mortality results for ovarian cancer screening in the PLCO trial with median 15years follow-up. Gynecol Oncol (2016) 0.79
Genetic variants in the fibroblast growth factor pathway as potential markers of ovarian cancer risk, therapeutic response, and clinical outcome. Clin Chem (2013) 0.79
Ovarian cancer in 2011: Mutations and non-inferiority analyses show a way forward. Nat Rev Clin Oncol (2011) 0.78
Ovarian cancer screening practices of obstetricians and gynecologists in puerto rico. Biomed Res Int (2014) 0.78
One step at a time: self-management and transitions among women with ovarian cancer. Oncol Nurs Forum (2012) 0.78
Limitations of three-dimensional power Doppler angiography in preoperative evaluation of ovarian tumors. J Ovarian Res (2015) 0.78
Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med (2011) 38.61
Mortality results from a randomized prostate-cancer screening trial. N Engl J Med (2009) 30.05
Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med (2012) 24.06
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med (2004) 23.44
A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet (2007) 22.96
Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet (2007) 21.18
Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet (2008) 17.65
The mutational landscape of head and neck squamous cell carcinoma. Science (2011) 16.88
Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med (2004) 15.10
Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA (2008) 13.35
Body-mass index and mortality among 1.46 million white adults. N Engl J Med (2010) 13.34
The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med (2007) 12.23
Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst (2012) 11.91
Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med (2012) 11.48
Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med (2003) 11.35
Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst (2008) 11.27
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med (2003) 11.25
A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med (2003) 9.18
Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA (2010) 8.93
A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nat Genet (2009) 8.39
Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood (2005) 8.37
Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med (2002) 8.09
Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. JAMA (2007) 7.93
50-year trends in smoking-related mortality in the United States. N Engl J Med (2013) 7.80
Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet (2009) 7.30
Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA (2006) 7.20
Understanding cancer treatment and outcomes: the Cancer Care Outcomes Research and Surveillance Consortium. J Clin Oncol (2004) 7.02
Reporting participation in epidemiologic studies: a survey of practice. Am J Epidemiol (2005) 6.52
Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. JAMA (2011) 6.45